Skip to content

Exacerbations and acute care

TL;DR — An asthma exacerbation is acute or subacute worsening beyond usual day-to-day variability that requires a treatment change; severity is determined by physiology and trajectory, not by the loudness of wheeze. Initial evidence-based care combines repeated inhaled short-acting β2-agonist, early systemic corticosteroid, oxygen titrated for hypoxemia, and ipratropium for severe presentations; IV magnesium is an adjunct for severe attacks not responding to initial therapy (Kew 2014, PMID 24865567). A quiet or “silent” chest, exhaustion, altered consciousness, poor respiratory effort, cyanosis/hypoxemia, hypotension or rising/normalizing PaCO2 despite distress indicate life threat and possible ventilatory failure (Garner 2022, PMID 35218742). Metered-dose inhaler plus spacer is at least as effective as nebulization for many children and shortens ED stay, so delivery should be chosen by severity and ability rather than ritual (Payares-Salamanca 2020, PMID 32940961). Discharge is a transition in prevention: start or optimize ICS-containing therapy, document technique and action plan, arrange follow-up and identify the failure chain behind the attack.

Defining the event

Exacerbation definitions vary across trials and practice. A widely used severe-event definition is worsening requiring at least three days of systemic corticosteroid, an ED visit requiring systemic steroid, or hospitalization (Reddel 2009, PMID 19535666).

Event label Typical operational elements Limitation
Worsening Increased symptoms/reliever or reduced PEF below personal pattern Captures early events but depends on diary behavior
Moderate exacerbation Treatment change and sustained worsening without systemic steroid/hospital threshold Definitions differ across studies
Severe exacerbation Systemic corticosteroid and/or ED/hospital event Treatment decision and access influence classification
Near-fatal asthma Hypercapnic respiratory failure, intubation/ventilation or similarly critical physiology Small heterogeneous population; documentation varies

The systemic-steroid definition is pragmatic, not biologically pure. A patient unable to access care may have a severe attack without receiving the treatment that would qualify the event.

Rapid assessment

Assessment and treatment proceed in parallel.

Domain Findings to record Why it matters
Speech/mental status Sentences, words, agitation, drowsiness, confusion Global respiratory reserve and cerebral oxygenation
Work of breathing Rate, accessory muscle use, retractions, paradox, fatigue Deteriorating effort can look deceptively calmer
Air entry/wheeze Bilateral entry, focality, silent chest Wheeze requires airflow; silence with distress is dangerous
Oxygenation Pulse oximetry and oxygen requirement Detects hypoxemia; waveform/perfusion affect reliability
Circulation Heart rate, blood pressure, pulsus and perfusion β-agonists and distress raise heart rate; hypotension is ominous
Objective airflow PEF/FEV1 when feasible without delaying treatment Supports severity and response, but cannot be performed by every critically ill patient
Prior risk ICU/intubation, recent systemic steroids, medication access Previous severe events predict future risk (Lowden 2022, PMID 36382233)

Normal or rising PaCO2 in a severely distressed patient is not reassuring: acute asthma usually produces hypocapnia; loss of ventilation can signal muscle fatigue and impending failure (Garner 2022, PMID 35218742).

Focal absent breath sounds, pleuritic pain, subcutaneous emphysema, fever/toxicity or unilateral findings should widen assessment to pneumothorax, pneumomediastinum, pneumonia, mucus plugging or foreign body.

First-line treatment bundle

Inhaled β2-agonist

Repeated inhaled albuterol/salbutamol is the principal bronchodilator. Dose and interval are titrated to severity and response; continuous delivery is used in critical disease.

Levalbuterol has not shown a consistent clinically important advantage over racemic albuterol in systematic review (Jat 2013, PMID 23207739).

High cumulative β2-agonist exposure can cause tremor, tachycardia, hypokalemia and type-B lactic acidosis. Rising lactate with improving airflow can produce persistent tachypnea that is mistaken for worsening bronchospasm, leading to a self-reinforcing dose cycle (Lewis 2014, PMID 23949578).

Ipratropium

Adding inhaled ipratropium to β2-agonist improves outcomes in moderate-to-severe emergency presentations, with greatest evidence early rather than as indefinite inpatient continuation (Chassany 2000, PMID 10866596; Silverman 2000, PMID 10650243).

Systemic corticosteroid

Systemic corticosteroid should be given early in significant attacks because genomic anti-inflammatory effects take hours. Oral administration is generally adequate when absorption and cooperation are reliable; IV delivery is reserved for inability to take/absorb oral drug or critical circumstances, not because it is intrinsically stronger (Fulco 2002, PMID 11918500).

Pediatric evidence supports one- or two-dose dexamethasone regimens as alternatives to multi-day prednisone/prednisolone in many settings, with adherence and vomiting advantages; equivalence depends on dose and outcome definition (Bravo-Soto 2017, PMID 28430773).

Oxygen

Supplemental oxygen treats hypoxemia and should be titrated rather than given at uncontrolled maximal concentration. Pulse oximetry is continuous context, not a replacement for clinical trajectory.

Delivery device

In children with mild-to-moderate attacks, pMDI plus spacer provides bronchodilator efficacy comparable to nebulization and can reduce ED length of stay; severe fatigue, very low inspiratory ability or ventilation circuits can change the delivery choice (Payares-Salamanca 2020, PMID 32940961).

Nebulization is not a severity treatment by itself. The delivered dose, oxygen/air driver, interface fit and infection-control context all matter.

Response reassessment

Reassess after each initial treatment cycle:

  • work of breathing and speech;
  • air entry, not wheeze alone;
  • oxygenation and circulation;
  • PEF/FEV1 when feasible;
  • bronchodilator interval needed to maintain improvement;
  • adverse effects and competing diagnoses.

Repeated dyspnea scores and percent predicted FEV1 are only modest predictors of hospitalization or relapse; disposition requires the full clinical pattern (Schneider 2014, PMID 25087835).

Second-line and adjunct therapies

Therapy Evidence position Main limitation/safety issue
IV magnesium sulfate Single-dose adjunct can reduce admission in selected severe adult attacks after inadequate initial response (Kew 2014, PMID 24865567) Hypotension/flushing; not routine for mild attacks
Nebulized magnesium Inconsistent pediatric/adult benefit Formulation and protocol heterogeneity (Kumar 2024, PMID 38782483)
IV β2-agonist Specialist/critical-care rescue when inhaled delivery fails Tachyarrhythmia, lactate, hypokalemia; weak comparative evidence
Aminophylline No routine role in most modern pathways Narrow therapeutic index and arrhythmia/seizure risk; limited incremental efficacy
Epinephrine Indicated when anaphylaxis is present; sometimes used in refractory critical bronchospasm Cardiovascular effects; selective inhaled β2-agonist remains standard for ordinary asthma (Baggott 2022, PMID 34593615)
Antibiotics Not routine without evidence of bacterial infection Most attacks are viral/nonbacterial; unnecessary adverse effects/resistance (Normansell 2018, PMID 29938789)

Adult meta-analysis found IV magnesium reduced hospital admission compared with placebo in severe acute asthma, with benefit concentrated in lower lung-function strata (Kew 2014, PMID 24865567). Pediatric reviews report heterogeneous results and protocols, so timing and selection remain unsettled (Ambrożej 2024, PMID 38395640).

Children: escalation from ED to ICU

Children deteriorate through rising work of breathing, hypoxemia, reduced air entry and exhaustion. Age-appropriate scores can standardize serial assessment but should not replace recognition of fatigue (Pardue 2016, PMID 27116362).

High-flow nasal cannula and noninvasive ventilation are increasingly used, but the evidence base is less mature than in bronchiolitis or COPD. Positive pressure can reduce work while also risking delayed intubation and dynamic hyperinflation (Chao 2021, PMID 33771473).

Second-line pediatric comparisons are limited by small trials and inconsistent outcomes; IV magnesium, IV β2-agonists and aminophylline should be embedded in monitored critical-care protocols rather than treated as equivalent menu items (Abu-Sultaneh 2025, PMID 40637351).

Noninvasive ventilation

NIV may reduce work of breathing in a cooperative patient without immediate intubation indications, but asthma evidence is largely observational and selected. Contraindications include impaired consciousness, inability to protect the airway, hemodynamic instability or rapidly worsening gas exchange (Homer-Bouthiette 2025, PMID 39642363).

The safety objective is not “avoid intubation at all costs.” It is to avoid unnecessary invasive ventilation without delaying it when fatigue or arrest risk rises.

Invasive ventilation

Mechanical ventilation in status asthmaticus is hazardous because severe expiratory flow limitation causes gas trapping and intrinsic PEEP.

Ventilation principle Physiologic purpose
Low respiratory rate and long expiratory time Allow exhalation; reduce breath stacking
Modest tidal volume and controlled minute ventilation Limit dynamic hyperinflation and barotrauma
High inspiratory flow Shorten inspiratory time
Accept permissive hypercapnia when appropriate Avoid injurious attempts to normalize CO2 immediately
Monitor plateau pressure and auto-PEEP Separate resistance-related peak pressure from alveolar pressure
Deep sedation, selective neuromuscular blockade Synchrony during extreme obstruction; minimize duration because steroid/neuromuscular combinations increase weakness risk

The principal mechanical danger is dynamic hyperinflation, which can cause hypotension, pneumothorax and arrest. A sudden hypotensive ventilated patient requires immediate consideration of gas trapping and tension pneumothorax (Laher 2018, PMID 29105540).

Ketamine and volatile anesthetics have bronchodilator properties and are reported in refractory cases, but evidence is mainly small studies/case series; they are rescue options within expert critical care, not routine first-line therapy (Goyal 2013, PMID 24082612).

Extracorporeal support is a rare salvage strategy for otherwise refractory hypercapnic failure/arrest in specialized centers; evidence is registry/case-based (Grennan 2022, PMID 36194100).

Disposition

Admission is favored by incomplete or short-lived response, persistent hypoxemia, low objective airflow, repeated bronchodilator need, prior near-fatal history, social/access barriers or diagnostic concern.

Discharge readiness requires sustained improvement at an interval compatible with home treatment, adequate oxygenation, ability to use medication/device, and a prevention plan.

Discharge as secondary prevention

Action Failure prevented
Start or optimize ICS-containing therapy Rebound untreated inflammation and future attacks
Check observed technique Prescription without lung delivery
Supply reliever/controller and resolve affordability Immediate treatment gap
Written action plan Unclear thresholds for escalation
Complete short systemic-steroid course when indicated Premature anti-inflammatory withdrawal
Early follow-up No review of recovery, diagnosis or precipitating chain
Review trigger and prior medication use Repetition of the same exposure/adherence failure

Personalized written action plans are effective when combined with education and regular review; a document without skills, medication and access is not the intervention (Gatheral 2017, PMID 28394084).

An ED randomized intervention improved primary-care follow-up by scheduling assistance, showing that transition failure can be modified operationally rather than merely advised (Baren 2001, PMID 11468604).

The post-attack review

Every severe attack should trigger a structured reconstruction:

  1. Was it asthma, and were alternatives/complications excluded?
  2. What exposure or infection preceded it?
  3. Was controller therapy prescribed, available, taken and delivered?
  4. Was reliever use escalating without an anti-inflammatory response?
  5. Was there a written plan, and could the patient act on it?
  6. Does the event change phenotype, severe-asthma or biologic eligibility?
  7. What system failure—cost, school/work permission, transport, pharmacy or follow-up—must be corrected?

Open questions

  • Which early physiologic trajectory best predicts need for ICU or ventilation beyond repeated FEV1/PEF and symptoms? (Schneider 2014, PMID 25087835)
  • Which pediatric second-line agent provides the best benefit–harm balance after initial inhaled therapy and steroid? (Abu-Sultaneh 2025, PMID 40637351)
  • Does NIV improve patient-centered outcomes or mainly shift intubation timing in selected severe asthma? (Homer-Bouthiette 2025, PMID 39642363)
  • Which discharge bundle reliably prevents 7- and 30-day relapse across resource settings?
  • Can acute biomarker-guided therapy improve outcomes without delaying universal bronchodilation and steroid care?

References

  1. Reddel HK, et al. ATS/ERS statement: asthma control and exacerbations—standardizing endpoints. Am J Respir Crit Care Med. 2009. PMID 19535666
  2. Garner O, et al. Management of life-threatening asthma. Chest. 2022. PMID 35218742
  3. Payares-Salamanca L, et al. Metered-dose inhalers versus nebulization for albuterol in children: systematic review and meta-analysis. Pediatr Pulmonol. 2020. PMID 32940961
  4. Lowden R, et al. Past asthma exacerbation in children predicting future exacerbation: systematic review. ERJ Open Res. 2022. PMID 36382233
  5. Jat KR, Khairwa A. Levalbuterol versus albuterol for acute asthma: systematic review and meta-analysis. Pulm Pharmacol Ther. 2013. PMID 23207739
  6. Lewis LM, et al. Albuterol administration and serum lactate in acute asthma. Chest. 2014. PMID 23949578
  7. Chassany O, et al. Ipratropium bromide in acute adult asthma: meta-analysis. Am J Med. 2000. PMID 10866596
  8. Silverman RA, et al. Ipratropium bromide in emergency management of acute asthma. Chest. 2000. PMID 10650243
  9. Fulco PP, et al. Intravenous versus oral corticosteroids for treatment of acute asthma exacerbations. Ann Pharmacother. 2002. PMID 11918500
  10. Bravo-Soto GA, et al. Is dexamethasone as effective as other corticosteroids for acute asthma exacerbation in children? Medwave. 2017. PMID 28430773
  11. Schneider SM, et al. Repeated dyspnea score and percent FEV1 are modest predictors of hospitalization/relapse. J Allergy Clin Immunol Pract. 2014. PMID 25087835
  12. Kew KM, Kirtchuk L, Michell CI. Intravenous magnesium sulfate for treating adults with acute asthma in the ED. Cochrane Database Syst Rev. 2014. PMID 24865567
  13. Kumar R, et al. Nebulised magnesium sulfate in acute asthma in children: systematic review and meta-analysis. Arch Dis Child. 2024. PMID 38782483
  14. Baggott C, et al. Epinephrine compared with selective beta-2 agonist in acute asthma: systematic review and meta-analysis. Thorax. 2022. PMID 34593615
  15. Normansell R, et al. Antibiotics for exacerbations of asthma. Cochrane Database Syst Rev. 2018. PMID 29938789
  16. Ambrożej D, et al. Intravenous magnesium sulfate for asthma exacerbations in children: systematic review with meta-analysis. Pediatr Pulmonol. 2024. PMID 38395640
  17. Pardue Jones B, et al. Pediatric acute asthma exacerbations: ED to ICU evaluation and management. J Asthma. 2016. PMID 27116362
  18. Chao KY, et al. High-flow nasal cannula in children with asthma exacerbation: review. J Asthma. 2021. PMID 33771473
  19. Abu-Sultaneh S, et al. Intravenous bronchodilators in pediatric critical asthma: systematic review and network meta-analysis. Crit Care. 2025. PMID 40637351
  20. Homer-Bouthiette C, et al. Noninvasive ventilation in acute asthma exacerbations: systematic review. Ann Am Thorac Soc. 2025. PMID 39642363
  21. Laher AE, et al. Mechanically ventilating the severe asthmatic. J Intensive Care Med. 2018. PMID 29105540
  22. Goyal S, et al. Ketamine in status asthmaticus: a review. Indian J Crit Care Med. 2013. PMID 24082612
  23. Grennan D, et al. Extracorporeal life support for status asthmaticus: outcomes in teens and young adults. ASAIO J. 2022. PMID 36194100
  24. Gatheral TL, et al. Personalised asthma action plans for adults with asthma. Cochrane Database Syst Rev. 2017. PMID 28394084
  25. Baren JM, et al. Emergency-department intervention to improve primary-care follow-up after acute asthma. Chest. 2001. PMID 11468604
  26. Hodder R, et al. Management of acute asthma in adults in the emergency department: nonventilatory management. CMAJ. 2010. PMID 19858243